查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143319

全身性紅斑性狼瘡治療市場：依藥物類型、給藥途徑、通路、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Systemic Lupus Erythematosus Treatment Market, By Drug Type, By Route of Administration, By Distribution Channel, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，全身性紅斑性狼瘡(SLE) 治療市場規模將達到 28.04 億美元，並預計從 2026 年到 2033 年將以 7.2% 的複合年成長率成長。

全身性紅斑性狼瘡(SLE) 的治療採用特殊方法，使用特定藥物來調節適應性免疫系統和固有免疫系統。這可以降低患者對疾病的易感性，預防症狀復發，並最大限度地減少疾病症狀造成的器官損害。藥物治療採用分層治療方案，而不考慮疾病的具體症狀。

具體而言，對於輕度症狀，通常聯合使用抗瘧疾藥和非類固醇消炎劑；而對於中度和重度症狀，則聯合使用糖皮質激素和免疫抑制劑。當涉及特定分子路徑時，生物製藥或標靶合成藥物治療可能被視為必要的治療手段。因此，這些療法可根據血清標記和患者的反應進行聯合應用。

全身性紅斑性狼瘡治療市場—市場動態

生物製藥的進步正在推動市場需求。

全身性紅斑性狼瘡(SLE)生物製藥療法的市場進展主要得益於對標靶藥物需求的成長、疾病管理水準的提高以及免疫抑制劑使用量的減少。抑制 B 細胞、I 型干擾素路徑以及其他導致 SLE 的免疫路徑的生物製藥的廣泛應用，正是這些進展的有力佐證。例如，英國製藥商和貿易商協會 (ABPI) 在 2026 年 3 月報告稱，製藥業開展的臨床試驗將為英國經濟帶來 100.1516 億美元的收入，為英國國家醫療服務體系 (NHS) 帶來 16.2408 億美元的收入，並創造 6.5 萬個新的就業機會。此外，英國還擁有 6,900 萬人的長期 NHS 醫療記錄，並已向健康數據研究服務 (Health Data Research Service) 投資 8.1204 億美元。這些進展正在增強臨床研究能力，並加速 SLE 創新生物製藥的研發。

全身性紅斑性狼瘡（SLE）治療市場－市場區隔分析：

全球全身性紅斑性狼瘡(SLE) 治療市場按藥物類型、給藥途徑、分銷管道和地區進行細分。

在藥物領域，預計到2025年，免疫抑制劑將佔全球狼瘡治療市場銷售額的35%以上。胺基甲基葉酸和Azathioprine等藥物有助於抑制發炎和免疫反應，因此可用於系統性紅斑狼瘡（SLE）的治療。治療需求規模龐大，根據美國疾病管制與預防中心（CDC）最新數據，美國約有20.4萬人患有SLE。在整個預測期內，持續的診斷和治療預計將支撐對免疫抑制劑的需求。

全身性紅斑性狼瘡(SLE) 治療市場－區域分析

由於北美地區現有的醫療保健系統和生物製藥基礎設施、有利的報銷率以及對專業免疫學服務日益成長的需求，預計北美仍將是主要市場。例如，根據美國過敏、氣喘和免疫學會 (AAAAI) 的報告，截至 2026 年 5 月，美國將有數百萬人受到氣喘和免疫疾病的影響。對過敏和免疫疾病的專業治療需求日益成長。據美國醫學會 (NMA) 稱，過敏和免疫疾病影響美國數百萬人。隨著對專業過敏和免疫學護理需求的成長，以及為了應對上述挑戰，截至 2026 年 5 月，NMA 過敏、氣喘和免疫學會、AAAI 和 ACAAI 將專注於培訓、指導、團隊合作和基於技術的醫療。這些組織計劃重點擴大對服務不足社區（例如偏遠地區和農村地區）的支持。

目錄

第1章：全身性紅斑性狼瘡治療市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：全身性紅斑性狼瘡治療的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：全身性紅斑性狼瘡治療藥物的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：全身性紅斑性狼瘡治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：全身性紅斑性狼瘡治療藥物的市場狀況

  • 全身性紅斑性狼瘡治療市佔率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：全身性紅斑性狼瘡治療市場：依藥物類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類型
    • 生物製劑
      • Safnero（阿尼弗魯單抗）
      • 貝利尤單抗（Benlysta）
      • 處於第 3 期臨床試驗階段的在研發線產品
    • 皮質類固醇
    • 抗瘧疾藥
    • TNF抑制劑
    • NSAID
    • 免疫抑制劑
    • 其他藥物分類

第8章：全身性紅斑性狼瘡治療市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 口服
    • 靜脈
    • 皮下
    • 其他

第9章：全身性紅斑性狼瘡治療市場：依分銷管道分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
    • 其他

第10章：全身性紅斑性狼瘡治療市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第11章：主要供應商分析：全身性紅斑性狼瘡治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • GSK plc
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd.
    • Aurinia Pharmaceuticals Inc.
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Eli Lilly and Company
    • Novartis AG
    • Sanofi
    • Merck & Co., Inc.
    • UCB SA
    • Biogen Inc.
    • Amgen Inc.
    • AbbVie Inc.
    • Johnson & Johnson（Janssen）
    • ImmuPharma plc
    • Kyverna Therapeutics
    • AnaptysBio, Inc.
    • Others

第12章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7539

Systemic Lupus Erythematosus Treatment market size was valued at US$ 2,800.4 Million in 2025, expanding at a CAGR of 7.2% from 2026 to 2033.

Systemic lupus Erythematosus Treatment represent a special treatment regimen involving the use of specific medicines for the purpose of regulating both the adaptive and innate immune systems. It allows achieving a condition where the patient becomes less affected by the disease without any disease flare-ups, and it causes minimum damage to the organs due to the manifestations of the disease. The drug treatment approach involves the use of a stratified therapeutic approach that is irrespective of any particular manifestation of the disease.

This involves the use of malarial medications together with nonsteroidal anti-inflammatory drugs in the case of mild manifestations of the disease, while the glucocorticoids together with immunosuppressant medications are used in the case of moderate and severe manifestations of the disease. In the case of some specific molecular pathways, the use of biological or targeted synthetic drug therapy might be considered as an essential treatment approach. Thus, allowing the combination of these therapies according to the serum markers and response of the patient.

Systemic Lupus Erythematosus Treatment Market- Market Dynamics

Advancements in Biologic Therapies to Drive Market Demand

The advancement of biologic therapies in the Systemic Lupus Erythematosus Treatment market is being fueled by increasing demands for target-based drugs, disease management, and reduction in immunosuppressive drug use. Increasing utilization of the biologics that block B cells, the type I interferon pathway, and other immune pathways that lead to SLE is evidence of such developments. For instance, in March 2026, according to the Association of the British Pharmaceutical Industry (Org), it was reported that the clinical trials conducted in the industry by the industry have generated revenues of for the UK economy ($10,015.16 million USD), for the NHS from NHS clinical trials ($1,624.08 million USD), and 65,000 additional jobs in 2026. Moreover, it has become clear that 69 million peoples' long-term NHS health records are available in the U.K., and in addition to that, has been invested in the Health Data Research Service ($812.04 million USD). These advancements strengthen clinical research capabilities and accelerate the development of innovative biologic therapies for SLE.

Systemic Lupus Erythematosus Treatment Market- Segmentation Analysis:

The Global Systemic Lupus Erythematosus Treatment market is segmented on the basis of Drug Type, Route of Administration, Distribution Channel, and Region.

In terms of drug type segment, the immunosuppressant segment accounted for over 35% of global lupus treatment revenue in 2025. Medicines such as methotrexate and azathioprine help control inflammation and immune activity, supporting their use in managing SLE. The scale of treatment need is substantial: the U.S. CDC estimates that 204,000 people have SLE in the United States, based on its most recent available data. Continued diagnosis and treatment are expected to support demand for immunosuppressants during the forecast period.

Systemic Lupus Erythematosus Treatment Market- Geographical Insights

North America is expected to remain a major market because of its already existing infrastructure for healthcare systems and biologicals, favorable reimbursement rates, and rising demand for specialty immunology services. For example, in May 2026, based on the report provided by the American College of Allergy, Asthma & Immunology (org), allergic and immunologic disorders affected millions of people in the United States. There has been a rising need for specialty treatment for allergic and immunologic disorders. Based on the National Medical Association (NMA), allergic and immunologic disorders have been affecting millions of people in America. There has been a rising demand for allergy and immunology specialty care, and in order to meet the above challenge, the NMA Allergy, Asthma, and Immunology Section; AAAAI; and ACAAI will concentrate on training, mentoring, teamwork, and technologically based care in May 2026. The organizations would focus on expanding their reach to those underserved communities that are isolated and rural.

Systemic Lupus Erythematosus Treatment Market- Competitive Landscape:

Competitive dynamics in the Systemic Lupus Erythematosus Treatment market will be influenced by how the leading players in the market will operate. This includes the leading companies that are working to establish their names in the market as market leaders through innovations and collaborations. These companies have been using innovation in treatment, physician sales, and physician and patient communication in order to distinguish themselves. In October 2025, Roche introduced an important novel treatment for lupus nephritis following the FDA's approval of Gazyva(R)/Gazyvaro(R) (obinutuzumab) for adults with active lupus nephritis on standard therapy. This approval followed the positive results of NOBILITY and REGENCY Phase II/III trials of the drug showing improvements in complete renal response compared to the standard therapy alone. These advancements are intensifying competition while accelerating innovation and expanding targeted treatment options for SLE.

Recent Developments:

In August 2025, Novartis presented Phase III clinical trial data for ianalumab, highlighting the positive opportunities associated with the drug concerning B-cell-mediated autoimmune conditions such as systemic lupus erythematosus. Ianalumab possesses dual B-cell depletion and BAFF-R inhibition properties and has been trialled for SLE and lupus nephritis.

In March 2025, Sanofi entered into an agreement with Dren Bio for purchasing DR-0201, a targeted bispecific myeloid cell engager that assists in deep B-cell depletion. The treatment has the possibility to provide benefits to patients suffering from difficult B-cell-mediated autoimmune diseases like lupus and enhance the immunology portfolio of the firm.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GSK plc
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Merck & Co., Inc.
  • UCB S.A.
  • Biogen Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Johnson & Johnson (Janssen)
  • ImmuPharma plc
  • Kyverna Therapeutics
  • AnaptysBio, Inc.
  • Others

GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2020 - 2033

  • Biologics
  • Saphnelo (Anifrolumab)
  • Benlysta (Belimumab)
  • Phase 3 Pipeline Products
  • Corticosteroids
  • Antimalarials
  • TNF Inhibitors
  • NSAID's
  • Immunosuppressants
  • Other Drug Classes

GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Oral
  • Intravenous
  • Subcutaneous
  • Others

GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Systemic Lupus Erythematosus Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
  • 2.2. Competitive Insights

3. Systemic Lupus Erythematosus Treatment Key Market Trends

  • 3.1. Systemic Lupus Erythematosus Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Systemic Lupus Erythematosus Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Systemic Lupus Erythematosus Treatment Market Opportunities
  • 3.4. Systemic Lupus Erythematosus Treatment Market Future Trends

4. Systemic Lupus Erythematosus Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Systemic Lupus Erythematosus Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Systemic Lupus Erythematosus Treatment Market Landscape

  • 6.1. Systemic Lupus Erythematosus Treatment Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Systemic Lupus Erythematosus Treatment Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2025 & 2033 (%)
    • 7.1.2. Biologics
      • 7.1.2.1. Saphnelo (Anifrolumab)
      • 7.1.2.2. Benlysta (Belimumab)
      • 7.1.2.3. Phase 3 Pipeline Products
    • 7.1.3. Corticosteroids
    • 7.1.4. Antimalarials
    • 7.1.5. TNF Inhibitors
    • 7.1.6. NSAID's
    • 7.1.7. Immunosuppressants
    • 7.1.8. Other Drug Classes

8. Systemic Lupus Erythematosus Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous
    • 8.1.4. Subcutaneous
    • 8.1.5. Others

9. Systemic Lupus Erythematosus Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 9.1.2. Hospital Pharmacy
    • 9.1.3. Retail Pharmacy
    • 9.1.4. Online Pharmacy
    • 9.1.5. Others

10. Systemic Lupus Erythematosus Treatment Market - By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Systemic Lupus Erythematosus Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Systemic Lupus Erythematosus Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Systemic Lupus Erythematosus Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Systemic Lupus Erythematosus Treatment Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Systemic Lupus Erythematosus Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Systemic Lupus Erythematosus Treatment Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
    • 11.2.2. AstraZeneca plc
    • 11.2.3. F. Hoffmann-La Roche Ltd.
    • 11.2.4. Aurinia Pharmaceuticals Inc.
    • 11.2.5. Pfizer Inc.
    • 11.2.6. Bristol Myers Squibb Company
    • 11.2.7. Eli Lilly and Company
    • 11.2.8. Novartis AG
    • 11.2.9. Sanofi
    • 11.2.10. Merck & Co., Inc.
    • 11.2.11. UCB S.A.
    • 11.2.12. Biogen Inc.
    • 11.2.13. Amgen Inc.
    • 11.2.14. AbbVie Inc.
    • 11.2.15. Johnson & Johnson (Janssen)
    • 11.2.16. ImmuPharma plc
    • 11.2.17. Kyverna Therapeutics
    • 11.2.18. AnaptysBio, Inc.
    • 11.2.19. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us